Showing results (171-180 of 261) with videos related to
Sort By:
Pageof 27
Dermatology and Therapy|August 23, 2024
Direct and Indirect Effect of Guselkumab on Anxiety, Depression, and Quality of Life in Patients with Moderate-to-Severe Plaque Psoriasis: A Mediation AnalysisApril W Armstrong, Peter Foley, Yan Liu, et al.The Australasian Journal of Dermatology|June 3, 2015
Consensus recommendations on the use of daylight photodynamic therapy with methyl aminolevulinate cream for actinic keratoses in AustraliaJo-Ann See, Stephen Shumack, Dedee F Murrell, et al.International Journal of Dermatology|July 29, 2024
A global perspective on the treatment and maintenance of mature skin using gentle cleansers and moisturizersJoachim W Fluhr, Andrew F Alexis, Anneke Andriessen, et al.Journal of the American Academy of Dermatology|December 28, 2006
Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005Lasse R Braathen, Rolf-Markus Szeimies, Nicole Basset-Seguin, et al.Plos One|March 29, 2024
Brain connectivity changes underlying depression and fatigue in relapsing-remitting multiple sclerosis: A systematic reviewAgniete Kampaite, Rebecka Gustafsson, Elizabeth N York, et al.Anesthesia and Analgesia|February 2, 2026
Exogenous Sex Hormones and Postoperative Nausea and Vomiting Risk in Transgender PatientsLeonard J Soloniuk, Jasmine Sran, Christopher Baker, et al.Seminars in Cardiothoracic and Vascular Anesthesia|June 26, 2026
Vasopressor Selection and Postoperative Delirium in Older Adults: A Propensity-Matched Database AnalysisTiffany Dong, William Mao, Christopher Baker, et al.The Australasian Journal of Dermatology|May 26, 2017
Psoriasis in those planning a family, pregnant or breast-feeding. The Australasian Psoriasis CollaborationMarius Rademaker, Karen Agnew, Megan Andrews, et al.Lancet (London, England)|February 7, 2021
Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trialKenneth B Gordon, Peter Foley, James G Krueger, et al.Journal of the American Academy of Dermatology|March 15, 2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III studyKim Papp, Herve Bachelez, Antonio Costanzo, et al.Pageof 27